Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Law Does Not Require Legislative Change, McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Legislation would slow implementation of the drug benefit, which is a primary goal of CMS, McClellan says. Overall savings will offset additional costs that the states take on under the federal “clawback,” he notes.

You may also be interested in...

Medicare Rx Law Will Stand The Test Of Time, Scully Says

Medicaid Cost-Containment Strategies May Include PDL For Antipsychotics

Increased flexibility in controlling drug costs will be required for states to maintain their bargaining power following the shift of “dual eligibles” to Medicare in 2006, Oklahoma Medicaid director says.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts